-
1
-
-
34547179997
-
MAP kinase pathways: The first twenty years
-
Avruch, J. MAP kinase pathways: The first twenty years. Biochim. Biophys. Acta, Mol. Cell Res., 2007, 1773 (8), 1150-1160.
-
(2007)
Biochim. Biophys. Acta, Mol. Cell Res.
, vol.1773
, Issue.8
, pp. 1150-1160
-
-
Avruch, J.1
-
2
-
-
0035212589
-
The ups and downs of MEK kinase interactions
-
Hagemann, C.; Blank, J. L. The ups and downs of MEK kinaseinteractions. Cell. Signal., 2001, 13 (12), 863-875.
-
(2001)
Cell. Signal.
, vol.13
, Issue.12
, pp. 863-875
-
-
Hagemann, C.1
Blank, J.L.2
-
3
-
-
34248591612
-
Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer
-
Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogenactivatedprotein kinase cascade for the treatment of cancer. Oncogene, 2007, 26 (22), 3291-310.
-
(2007)
Oncogene
, vol.26
, Issue.22
, pp. 3291-3310
-
-
Roberts, P.J.1
Der, C.J.2
-
4
-
-
34547482919
-
Clinical experience of MEK inhibitors in cancer therapy
-
Wang, D.; Boerner, S. A.; Winkler, J. D.; LoRusso, P. M. Clinicalexperience of MEK inhibitors in cancer therapy. Biochim. Biophys. Acta., 2007, 1773 (8), 1248-1255.
-
(2007)
Biochim. Biophys. Acta.
, vol.1773
, Issue.8
, pp. 1248-1255
-
-
Wang, D.1
Boerner, S.A.2
Winkler, J.D.3
Lorusso, P.M.4
-
5
-
-
0038664387
-
BRAF mutation in papillary thyroid carcinoma
-
Cohen Y.; Xing, M.; Mambo, E.; Guo, Z.; Wu, G.; Trink, B.; Beller, U.; Westra, W. H.; Ladenson, P. W.; Sidransky, D. BRAFmutation in papillary thyroid carcinoma. J. Natl. Cancer I., 2003, 95(8), 625-627.
-
(2003)
J. Natl. Cancer I.
, vol.95
, Issue.8
, pp. 625-627
-
-
Cohen, Y.1
Xing, M.2
Mambo, E.3
Guo, Z.4
Wu, G.5
Trink, B.6
Beller, U.7
Westra, W.H.8
Ladenson, P.W.9
Sidransky, D.10
-
6
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; -Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417 (6892), 949-954.
-
(2002)
Nature
, vol.417
, Issue.6892
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
Davis, N.11
Dicks, E.12
Ewing, R.13
Floyd, Y.14
Gray, K.15
Hall, S.16
Hawes, R.17
Hughes, J.18
Kosmidou, V.19
Menzies, A.20
Mould, C.21
Parker, A.22
Stevens, C.23
Watt, S.24
Hooper, S.25
Wilson, R.26
Jayatilake, H.27
Gusterson, B.A.28
Cooper, C.29
Shipley, J.30
Hargrave, D.31
Pritchard-Jones, K.32
Maitland, N.33
Chenevix-Trench, G.34
Riggins, G.J.35
Bigner, D.D.36
Palmieri, G.37
Cossu, A.38
Flanagan, A.39
Nicholson, A.40
Ho, J.W.C.41
Leung, S.Y.42
Yuen, S.T.43
Weber, B.L.44
Seigler, H.F.45
Darrow, T.L.46
Paterson, H.47
Marais, R.48
Marshall, C.J.49
Wooster, R.50
Stratton, M.R.51
Futreal, P.A.52
more..
-
7
-
-
0041589377
-
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines
-
Xu X.; Quiros, R. M.; Gattuso, P.; Ain, K. B.; Prinz, R. A. Highprevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res., 2003, 63 (15), 4561-4567.
-
(2003)
Cancer Res.
, vol.63
, Issue.15
, pp. 4561-4567
-
-
Xu, X.1
Quiros, R.M.2
Gattuso, P.3
Ain, K.B.4
Prinz, R.A.5
-
8
-
-
33745063617
-
Recent progress in development of non-ATP competitive smallmolecule inhibitors of protein kinases
-
Kiselyov, A.; Balakin, K. V.; Tkachenko, S. E.; Savchuk, N. P. Recent progress in development of non-ATP competitive smallmoleculeinhibitors of protein kinases. Mini-Rev. Med. Chem., 2006, 6(6), 711-717.
-
(2006)
Mini-Rev. Med. Chem.
, vol.6
, Issue.6
, pp. 711-717
-
-
Kiselyov, A.1
Balakin, K.V.2
Tkachenko, S.E.3
Savchuk, N.P.4
-
9
-
-
84861494447
-
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1, 2 inhibitors possessing bidentate Ser212interactions
-
Heald, R. A.; Jackson, P.; Savy, P.; Jones, M.; Gancia, E.; Burton, B.; Newman, R.; Boggs, J.; Chan, E.; Chan, J.; Choo, E.; Merchant, M.; Rudewicz, P.; Ultsch, M.; Wiesmann, C.; Yue, Q.; Belvin, M.; Price, S. Discovery of novel allosteric mitogen-activated proteinkinase kinase (MEK) 1, 2 inhibitors possessing bidentate Ser212interactions. J. Med. Chem., 2012, 55(10), 4594-4604.
-
(2012)
J. Med. Chem.
, vol.55
, Issue.10
, pp. 4594-4604
-
-
Heald, R.A.1
Jackson, P.2
Savy, P.3
Jones, M.4
Gancia, E.5
Burton, B.6
Newman, R.7
Boggs, J.8
Chan, E.9
Chan, J.10
Choo, E.11
Merchant, M.12
Rudewicz, P.13
Ultsch, M.14
Wiesmann, C.15
Yue, Q.16
Belvin, M.17
Price, S.18
-
10
-
-
84855894652
-
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
-
Santarpia, L.; Lippman, S. M.; El-Naggar, A. K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 2012, 16 (1), 103-119.
-
(2012)
Expert Opin. Ther. Targets
, vol.16
, Issue.1
, pp. 103-119
-
-
Santarpia, L.1
Lippman, S.M.2
El-Naggar, A.K.3
-
11
-
-
84858227014
-
RAS/RAF/MEK inhibitors in oncology
-
Rusconi, P.; Caiola, E.; Broggini, M. RAS/RAF/MEK inhibitors inoncology. Curr. Med. Chem., 2012, 19(8), 1164-1176.
-
(2012)
Curr. Med. Chem.
, vol.19
, Issue.8
, pp. 1164-1176
-
-
Rusconi, P.1
Caiola, E.2
Broggini, M.3
-
12
-
-
46849116601
-
Putative allosteric MEK1 and MEK2 inhibitors
-
Price, S. Putative allosteric MEK1 and MEK2 inhibitors. ExpertOpin. Ther. Pat., 2008, 18(6), 603-627.
-
(2008)
ExpertOpin. Ther. Pat.
, vol.18
, Issue.6
, pp. 603-627
-
-
Price, S.1
-
13
-
-
15744380263
-
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition
-
Ohren, J. F.; Chen, H. F.; Pavlovsky, A.; Whitehead, C.; Zhang, E.L.; Kuffa, P.; Yan, C. H.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W. T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D. T.; Leung, I. K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C. A. Structures of human MAPkinase kinase 1 (MEK1) and MEK2 describe novel noncompetitivekinase inhibition. Nat. Struct. Mol. Biol., 2004, 11(12), 1192-1197.
-
(2004)
Nat. Struct. Mol. Biol.
, vol.11
, Issue.12
, pp. 1192-1197
-
-
Ohren, J.F.1
Chen, H.F.2
Pavlovsky, A.3
Whitehead, C.4
Zhang, E.L.5
Kuffa, P.6
Yan, C.H.7
McConnell, P.8
Spessard, C.9
Banotai, C.10
Mueller, W.T.11
Delaney, A.12
Omer, C.13
Sebolt-Leopold, J.14
Dudley, D.T.15
Leung, I.K.16
Flamme, C.17
Warmus, J.18
Kaufman, M.19
Barrett, S.20
Tecle, H.21
Hasemann, C.A.22
more..
-
14
-
-
79959444801
-
MEK inhibitors: A patent review 2008 -2010
-
Trujillo, J. I. MEK inhibitors: a patent review 2008 -2010. ExpertOpin. Ther. Pat., 2011, 21(7), 1045-1069.
-
(2011)
Expert Opin. Ther. Pat.
, vol.21
, Issue.7
, pp. 1045-1069
-
-
Trujillo, J.I.1
-
15
-
-
10744227031
-
Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors
-
Wityak, J.; Hobbs, F. W.; Gardner, D. S.; Santella, J. B., 3rd;Petraitis, J. J.; Sun, J. H.; Favata, M. F.; Daulerio, A. J.; Horiuchi, K. Y.; Copeland, R. A.; Scherle, P. A.; Jaffe, B. D.; Trzaskos, J.M.; Magolda, R. L.; Trainor, G. L.; Duncia, J. V. Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series ofpotent MEK inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(6), 1483-1486.
-
(2004)
Bioorg. Med. Chem. Lett.
, vol.14
, Issue.6
, pp. 1483-1486
-
-
Wityak, J.1
Hobbs, F.W.2
Gardner, D.S.3
Santella III, J.B.4
Petraitis, J.J.5
Sun, J.H.6
Favata, M.F.7
Daulerio, A.J.8
Horiuchi, K.Y.9
Copeland, R.A.10
Scherle, P.A.11
Jaffe, B.D.12
Trzaskos, J.M.13
Magolda, R.L.14
Trainor, G.L.15
Duncia, J.V.16
-
16
-
-
84887869936
-
-
WO2003035626, October 23
-
Arkinstall, S. J.; Arulanandam, A.; Jiang, X.; Magar, S.; Nabioullin, R.; Zhang, J. Y.; Blume-Jensen, P. Preparation of N-(imidazolylmethyl)benzamides and imidazolylalkyl-benzoates asMEK-1 and ERK-2 kinase inhibitors. WO2003035626, October 23, 2002.
-
(2002)
Preparation of N-(imidazolylmethyl)benzamides and Imidazolylalkyl- benzoates As MEK-1 and ERK-2 Kinase Inhibitors
-
-
Arkinstall, S.J.1
Arulanandam, A.2
Jiang, X.3
Magar, S.4
Nabioullin, R.5
Zhang, J.Y.6
Blume-Jensen, P.7
-
17
-
-
84887940032
-
Novel, orally bioavailable N-substituted imidazolebased MEK inhibitors as potential anticancer agents
-
San Francisco, CA, United States, Sept. 10-14, MEDI-580
-
Goutopoulos, A.; Sutton, A.; Karra, S.; Xu, Q.; Fischer, D.; Zhang, W.; Hum, C.; Brugger, N.; Healey, B.; Luo, Z.; McGregor, M.; Jiang, X.; Ramamurthy, A.; Murray, R.; Magar, S.; Blume-Jensen, P.; Zhang, J.; Nabioullin, R.; Arulandandam, T.; Tepper, M.; Askew, B.; Arkinstall, S.; Marinelli, P.; Golzio, L.; Giachetti, C.; Schwarz, M. Novel, orally bioavailable N-substituted imidazolebasedMEK inhibitors as potential anticancer agents. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, UnitedStates, Sept. 10-14, 2006, MEDI-580.
-
(2006)
Abstracts of Papers, 232nd ACS National Meeting
-
-
Goutopoulos, A.1
Sutton, A.2
Karra, S.3
Xu, Q.4
Fischer, D.5
Zhang, W.6
Hum, C.7
Brugger, N.8
Healey, B.9
Luo, Z.10
McGregor, M.11
Jiang, X.12
Ramamurthy, A.13
Murray, R.14
Magar, S.15
Blume-Jensen, P.16
Zhang, J.17
Nabioullin, R.18
Arulandandam, T.19
Tepper, M.20
Askew, B.21
Arkinstall, S.22
Marinelli, P.23
Golzio, L.24
Giachetti, C.25
Schwarz, M.26
more..
-
18
-
-
27644515238
-
Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors
-
Han, S.; Zhou, V.; Pan, S.; Liu, Y.; Hornsby, M.; McMullan, D.; Klock, H. E.; Haugen, J.; Lesley, S. A.; Gray, N.; Caldwell, J.; Gu, X. J. Identification of coumarin derivatives as a novel class ofallosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(24), 5467-5473.
-
(2005)
Bioorg. Med. Chem. Lett.
, vol.15
, Issue.24
, pp. 5467-5473
-
-
Han, S.1
Zhou, V.2
Pan, S.3
Liu, Y.4
Hornsby, M.5
McMullan, D.6
Klock, H.E.7
Haugen, J.8
Lesley, S.A.9
Gray, N.10
Caldwell, J.11
Gu, X.J.12
-
19
-
-
73949091523
-
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel mek1/2 kinase inhibitor ro5068760 in multiple tumor models
-
Daouti, S.; Higgins, B.; Kolinsky, K.; Packman, K.; Wang, H.; Rizzo, C.; Moliterni, J.; Huby, N.; Fotouhi, N.; Liu, M.; Goelzer, P.; Sandhu, H. K.; Li, J. K.; Railkar, A.; Heimbrook, D.; Niu, H. Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase InhibitorRO5068760 in Multiple Tumor Models. Mol. Cancer Ther., 2010, 9(1), 134-144.
-
(2010)
Mol. Cancer Ther.
, vol.9
, Issue.1
, pp. 134-144
-
-
Daouti, S.1
Higgins, B.2
Kolinsky, K.3
Packman, K.4
Wang, H.5
Rizzo, C.6
Moliterni, J.7
Huby, N.8
Fotouhi, N.9
Liu, M.10
Goelzer, P.11
Sandhu, H.K.12
Li, J.K.13
Railkar, A.14
Heimbrook, D.15
Niu, H.16
-
20
-
-
78649790745
-
The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: Assessment of target suppression
-
Lee, L.; Niu, H.; Goelzer, P.; Rueger, R.; Deutsch, J.; Busse-Reid, R.; DeSchepper, S.; Blotner, S.; Barrett, J.; Weissgerber, G.; Peck, R. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, inhealthy volunteers: assessment of target suppression. J. Clin. Pharmacol., 2010, 50(12), 1397-1405.
-
(2010)
J. Clin. Pharmacol.
, vol.50
, Issue.12
, pp. 1397-1405
-
-
Lee, L.1
Niu, H.2
Goelzer, P.3
Rueger, R.4
Deutsch, J.5
Busse-Reid, R.6
Deschepper, S.7
Blotner, S.8
Barrett, J.9
Weissgerber, G.10
Peck, R.11
-
21
-
-
77950643074
-
Coumarins: Old compounds with novel promising therapeutic perspectives
-
Riveiro, M. E.; De Kimpe, N.; Moglioni, A.; Vazquez, R.; Monczor, F.; Shayo, C.; Davio, C. Coumarins: old compounds withnovel promising therapeutic perspectives. Curr. Med. Chem., 2010, 17(13), 1325-1338.
-
(2010)
Curr. Med. Chem.
, vol.17
, Issue.13
, pp. 1325-1338
-
-
Riveiro, M.E.1
De Kimpe, N.2
Moglioni, A.3
Vazquez, R.4
Monczor, F.5
Shayo, C.6
Davio, C.7
-
22
-
-
11444268281
-
Synthetic and natural coumarins as cytotoxic agents
-
Kostova, I. Synthetic and natural coumarins as cytotoxic agents. Anti-Cancer Agents Med. Chem., 2005, 5(1), 29-46.
-
(2005)
Anti-Cancer Agents Med. Chem.
, vol.5
, Issue.1
, pp. 29-46
-
-
Kostova, I.1
-
23
-
-
84866863717
-
7-Alkyl-3-benzylcoumarins: A versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists
-
Rempel, V.; Volz, N.; Hinz, S.; Karcz, T.; Meliciani, I.; Nieger, M.; Wenzel, W.; Brase, S.; Muller, C. E. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. J. Med. Chem., 2012, 55(18), 7967-7977.
-
(2012)
J. Med. Chem.
, vol.55
, Issue.18
, pp. 7967-7977
-
-
Rempel, V.1
Volz, N.2
Hinz, S.3
Karcz, T.4
Meliciani, I.5
Nieger, M.6
Wenzel, W.7
Brase, S.8
Muller, C.E.9
-
24
-
-
0032767738
-
Coumarin metabolism, toxicity and carcinogenicity: Relevance for human risk assessment
-
Lake, B. G. Coumarin Metabolism, Toxicity and Carcinogenicity:Relevance for Human Risk Assessment. Food Chem. Toxicol., 1999, 37 (4), 423-453.
-
(1999)
Food Chem. Toxicol.
, vol.37
, Issue.4
, pp. 423-453
-
-
Lake, B.G.1
-
25
-
-
20044366228
-
LC Determination of coumarin-3-acyl derivatives for evaluation of the stability and monoamine oxidase inhibition mechanism
-
Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Gagliardi, L.; De Orsi, D. LC Determination of coumarin-3-acylderivatives for evaluation of the stability and monoamine oxidaseinhibition mechanism. Chromatographia, 2005, 61 (9-10), 519-522.
-
(2005)
Chromatographia
, vol.61
, Issue.9-10
, pp. 519-522
-
-
Chimenti, F.1
Secci, D.2
Bolasco, A.3
Chimenti, P.4
Granese, A.5
Gagliardi, L.6
De Orsi, D.7
-
26
-
-
84878272373
-
Substituted 3-benzyl coumarins as allosteric mek1 inhibitors: Design, synthesis and biological evaluations as antiviral agents
-
(accepted)
-
Wang C.; Zhang H.; Xu F.; Niu Y.; Wu Y.; Wang X.; Peng Y.; SunJ.; Liang L.; Xu P. Substituted 3-Benzyl Coumarins as AllostericMEK1 Inhibitors: Design, Synthesis and Biological Evaluations asAntiviral Agents. Molecules, 2013, 18, 1-x(accepted).
-
(2013)
Molecules
, vol.18
-
-
Wang, C.1
Zhang, H.2
Xu, F.3
Niu, Y.4
Wu, Y.5
Wang, X.6
Peng, Y.7
Sun, J.8
Liang, L.9
Xu, P.10
-
27
-
-
84871107842
-
Comparison of the efficiencies of two trfret methods to detect in vitro natural and synthesized inhibitors of the raf/mek/erk signaling pathway
-
S.R. Fabienne Saab, Jean-Yves Mérour, Valérie Bénéteau, Françoise Schoentgen. Comparison of the efficiencies of two TRFRETmethods to detect in vitro natural and synthesized inhibitors of the Raf/MEK/ERK signaling pathway. International Journal of High Throughput Screening, 2010, 1, 81-98.
-
(2010)
International Journal of High Throughput Screening
, vol.1
, pp. 81-98
-
-
Fabienne Saab, S.R.1
Mérour, J.-Y.2
Bénéteau, V.3
Schoentgen, F.4
-
28
-
-
84887896712
-
-
(Accessed May 17)
-
http://www.ccdc.cam.ac.uk/products/life-sciences/gold/. (AccessedMay 17, 2013).
-
(2013)
-
-
|